Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial of Selective Index Lymph Node Resection Versus Therapeutic Lymph Node Dissection After Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma

NCT07049276 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT07049276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07049276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial of Selective Index Lymph Node Resection Versus Therapeutic Lymph Node Dissection After Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma
Lead sponsor
Melanoma Institute Australia
Phase
Not applicable
Overall status
Recruiting
Start date
October 1, 2025
Completion date
August 31, 2040
Enrollment
1,500 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, stage iii